Pressmeddelande -

TATAA Biocenter listed as one of Sweden's fastest growing tech companies

TATAA Biocenter is listed as one of Sweden's fastest growing tech companies by accounting organization Deloitte. Sweden Technology Fast 50 includes public and private companies in all areas of technology, from software and hardware to life science, communications and clean technology. The ranking is based on the companies average revenue increase during a 4-year period. 

 - It is an impressive effort by our employees growing TATAA Biocenter from a teaching platform to one of Europe's leading companies serving the Pharmaceutical and Biotech industries. It bodes well for the efforts on cell and gene therapy and international expansion TATAA Biocenter initiated this year, says Mikael Kubista, CEO.

– We are excited to recognize and celebrate the companies in this year’s Deloitte Sweden Technology Fast 50. The companies ranked, and the smart solutions and services they provide, reflect Sweden’s position at the forefront of innovation, entrepreneurship and digital transformation. Qualifying for a place on the list is a significant achievement and we look forward to seeing what’s next for these companies, says Ester Sundström, partner and responsible for Deloitte Sweden Technology Fast 50.
.

Relaterade länkar

Ämnen

  • Hälsa, sjukvård, läkemedel

Kategorier

  • #cellandgene
  • #fast50se
  • #qpcr
  • #proteomics
  • #growth
  • #deloitte
  • #tataa
  • #atmp
  • #ngs

TATAA Biocenter is leading provider of molecular service as center to the Advanced Therapies and Medical products (ATMP) industry in Europe and the Cell and Gene Therapy in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP) TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling including genomics, transcriptomics, proteomics and microbiomics with traditional qPCR, dPCR and NGS methods as well as proprietary methods such as Two-Tailed PCR and Direct Blood Genotyping.

Kontakter

Mikael Kubista

Presskontakt CEO Cell and Gene Therapy +46733928168

Romina Cifliku

Presskontakt Project Manager +46 728815843

Relaterat innehåll